Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function

Authors: Jeannine Bachmann, Knut Ketterer, Christiane Marsch, Kerstin Fechtner, Holger Krakowski-Roosen, Markus W Büchler, Helmut Friess, Marc E Martignoni

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Dramatic weight loss is an often underestimated symptom in pancreatic cancer patients. Cachexia- defined as an unintended loss of stable weight exceeding 10% – is present in up to 80% of patients with cancer of the upper gastrointestinal tract, and has a significant influence on survival. The aim of the study was to show the multiple systemic effects of cachexia in pancreatic cancer patients, in terms of resection rate, effects on pulmonary function, amount of fat and muscle tissue, as well as changes in laboratory parameters.

Methods

In patients with pancreatic cancer, clinical appearance was documented, including the amount of weight loss. Laboratory parameters and lung-function tests were evaluated, and the thickness of muscle and fat tissue was measured with computed tomography scans. Statistical analysis, including multivariate analysis, was performed using SPSS software. Survival curves were calculated using Kaplan-Meier analysis and the log-rank test. To test for significant differences between the examined groups we used Student's t-test and the Mann-Whitney U test. Significance was defined as p < 0.05.

Results

Of 198 patients with a ductal adenocarcinoma of the pancreas, 70% were suffering from weight loss when they presented for operation, and in 40% weight loss exceeded 10% of the stable weight. In patients with cachexia, metastases were diagnosed significantly more often (47% vs. 24%, P < 0.001), leading to a significantly reduced resection rate in these patients. Patients with cachexia had significantly reduced fat tissue amounts. Hence, dramatic weight loss in a patient with pancreatic cancer may be a hint of a more progressed or more aggressive tumour.

Conclusion

Pancreatic cancer patients with cachexia had a higher rate of more progressed tumour stages and a worse nutritional status. Furthermore, patients with cachexia had an impaired lung function and a reduction in fat tissue. Patients with pancreatic cancer and cachexia had significantly reduced survival. If weight loss exceeded 5% there was a significantly reduced resection rate to detect, but the changes were significantly more substantial if weight loss was 10% or more. We propose that a weight loss of 10% be defined as significant in pancreatic cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005, 54: 385-387. 10.1136/gut.2004.047191.CrossRefPubMedPubMedCentral Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005, 54: 385-387. 10.1136/gut.2004.047191.CrossRefPubMedPubMedCentral
2.
go back to reference Friess H, Isenmann R, Berberat P, Kleeff J, Buchler MW: [Prognosis in pancreatic carcinoma]. Ther Umsch. 1996, 53 (5): 401-407.PubMed Friess H, Isenmann R, Berberat P, Kleeff J, Buchler MW: [Prognosis in pancreatic carcinoma]. Ther Umsch. 1996, 53 (5): 401-407.PubMed
3.
go back to reference Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics. CA Cancer J Clin. 2005, 55: 10-30. 10.3322/canjclin.55.1.10.CrossRefPubMed Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics. CA Cancer J Clin. 2005, 55: 10-30. 10.3322/canjclin.55.1.10.CrossRefPubMed
4.
go back to reference Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003, 27: 1075-1084. 10.1007/s00268-003-7165-7.CrossRefPubMed Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003, 27: 1075-1084. 10.1007/s00268-003-7165-7.CrossRefPubMed
5.
go back to reference Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996, 223: 273-279. 10.1097/00000658-199603000-00007.CrossRefPubMedPubMedCentral Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996, 223: 273-279. 10.1097/00000658-199603000-00007.CrossRefPubMedPubMedCentral
6.
go back to reference Cooperman AM: Pancreatic cancer: the bigger picture. Surg Clin North Am. 2001, 81: 557-574. 10.1016/S0039-6109(05)70143-2.CrossRefPubMed Cooperman AM: Pancreatic cancer: the bigger picture. Surg Clin North Am. 2001, 81: 557-574. 10.1016/S0039-6109(05)70143-2.CrossRefPubMed
7.
go back to reference Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, Ogata Y, Hishinuma S, Asano T, Aikou T, Hosotani R, Maetani S: A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery. 2004, 136: 1003-1011. 10.1016/j.surg.2004.04.030.CrossRefPubMed Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, Ogata Y, Hishinuma S, Asano T, Aikou T, Hosotani R, Maetani S: A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery. 2004, 136: 1003-1011. 10.1016/j.surg.2004.04.030.CrossRefPubMed
8.
go back to reference Kleeff J, Michalski C, Friess H, Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006, 33: 111-118. 10.1097/01.mpa.0000229010.62538.f2.CrossRefPubMed Kleeff J, Michalski C, Friess H, Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006, 33: 111-118. 10.1097/01.mpa.0000229010.62538.f2.CrossRefPubMed
9.
go back to reference Kleeff J, Michalski CW, Friess H, Buchler MW: Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. Eur J Surg Oncol. 2007, 33: 817-823.CrossRefPubMed Kleeff J, Michalski CW, Friess H, Buchler MW: Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. Eur J Surg Oncol. 2007, 33: 817-823.CrossRefPubMed
10.
go back to reference Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004, 91: 586-594. 10.1002/bjs.4484.CrossRefPubMed Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004, 91: 586-594. 10.1002/bjs.4484.CrossRefPubMed
11.
go back to reference Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. American family physician. 2006, 73: 485-492.PubMed Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. American family physician. 2006, 73: 485-492.PubMed
12.
go back to reference Dank M: [Tumorus anorexia/cachexia syndrome]. Magy Onkol. 2001, 45: 431-436.PubMed Dank M: [Tumorus anorexia/cachexia syndrome]. Magy Onkol. 2001, 45: 431-436.PubMed
13.
go back to reference DiMagno EP: Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999, 10: 140-142. 10.1023/A:1008382029375.CrossRefPubMed DiMagno EP: Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999, 10: 140-142. 10.1023/A:1008382029375.CrossRefPubMed
14.
go back to reference Ockenga J, Pirlich M, Gastell S, Lochs H: Tumour anorexia–tumour cachexia in case of gastrointestinal tumours: standards and visions. Zeitschrift fur Gastroenterologie. 2002, 40: 929-936. 10.1055/s-2002-35411.CrossRefPubMed Ockenga J, Pirlich M, Gastell S, Lochs H: Tumour anorexia–tumour cachexia in case of gastrointestinal tumours: standards and visions. Zeitschrift fur Gastroenterologie. 2002, 40: 929-936. 10.1055/s-2002-35411.CrossRefPubMed
15.
go back to reference Deans C, Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005, 8: 265-269.CrossRefPubMed Deans C, Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005, 8: 265-269.CrossRefPubMed
16.
go back to reference Davidson W, Ash S, Capra S, Bauer J, Cancer Cachexia Study Group: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004, 23: 239-247. 10.1016/j.clnu.2003.07.001.CrossRefPubMed Davidson W, Ash S, Capra S, Bauer J, Cancer Cachexia Study Group: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004, 23: 239-247. 10.1016/j.clnu.2003.07.001.CrossRefPubMed
17.
go back to reference Costelli P, Baccino FM: Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care. 2003, 6: 407-412. 10.1097/00075197-200307000-00009.PubMed Costelli P, Baccino FM: Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care. 2003, 6: 407-412. 10.1097/00075197-200307000-00009.PubMed
18.
go back to reference Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995, 75: 2077-2082. 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9.CrossRefPubMed Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995, 75: 2077-2082. 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9.CrossRefPubMed
19.
go back to reference Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T: Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999, 23: 584-588. 10.1007/PL00012351.CrossRefPubMed Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T: Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999, 23: 584-588. 10.1007/PL00012351.CrossRefPubMed
20.
21.
go back to reference Bosaeus I, Daneryd P, Svanberg E, Lundholm K: Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001, 93: 380-383. 10.1002/ijc.1332.CrossRefPubMed Bosaeus I, Daneryd P, Svanberg E, Lundholm K: Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001, 93: 380-383. 10.1002/ijc.1332.CrossRefPubMed
22.
go back to reference Camps C, Iranzo V, Bremnes RM, Sirera R: Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Support Care Cancer. 2006, 14: 1173-1183. 10.1007/s00520-006-0097-7.CrossRefPubMed Camps C, Iranzo V, Bremnes RM, Sirera R: Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Support Care Cancer. 2006, 14: 1173-1183. 10.1007/s00520-006-0097-7.CrossRefPubMed
23.
go back to reference Agustsson T, Ryden M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, Isaksson B, Permert J, Arner P: Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67: 5531-5537. 10.1158/0008-5472.CAN-06-4585.CrossRefPubMed Agustsson T, Ryden M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, Isaksson B, Permert J, Arner P: Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67: 5531-5537. 10.1158/0008-5472.CAN-06-4585.CrossRefPubMed
24.
go back to reference Inui A: Cancer anorexia-cachexia syndrome: are neuropeptides the key?. Cancer Res. 1999, 59 (18): 4493-4501.PubMed Inui A: Cancer anorexia-cachexia syndrome: are neuropeptides the key?. Cancer Res. 1999, 59 (18): 4493-4501.PubMed
25.
go back to reference Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F: Therapy insight: Cancer anorexia-cachexia syndrome–when all you can eat is yourself. Nat Clin Pract Oncol. 2005, 2: 158-165. 10.1038/ncponc0112.CrossRefPubMed Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F: Therapy insight: Cancer anorexia-cachexia syndrome–when all you can eat is yourself. Nat Clin Pract Oncol. 2005, 2: 158-165. 10.1038/ncponc0112.CrossRefPubMed
26.
go back to reference Nelson KA: Modern management of the cancer anorexia-cachexia syndrome. Curr Oncol Rep. 2000, 2: 362-368. 10.1007/s11912-000-0031-y.CrossRefPubMed Nelson KA: Modern management of the cancer anorexia-cachexia syndrome. Curr Oncol Rep. 2000, 2: 362-368. 10.1007/s11912-000-0031-y.CrossRefPubMed
27.
go back to reference Ripamonti C: Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999, 7 (4): 233-243. 10.1007/s005200050255.CrossRefPubMed Ripamonti C: Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999, 7 (4): 233-243. 10.1007/s005200050255.CrossRefPubMed
28.
go back to reference Ripamonti C, Fusco F: Respiratory problems in advanced cancer. Supportive care in cancer: Official journal of the Multinational Association of Supportive. Support Care Cancer. 2002, 10 (3): 204-216. 10.1007/s005200100296.CrossRefPubMed Ripamonti C, Fusco F: Respiratory problems in advanced cancer. Supportive care in cancer: Official journal of the Multinational Association of Supportive. Support Care Cancer. 2002, 10 (3): 204-216. 10.1007/s005200100296.CrossRefPubMed
29.
go back to reference Kispert JF, Kazmers A, Roitman L: Preoperative spirometry predicts perioperative pulmonary complications after major vascular surgery. Am Surg. 1992, 58: 491-495.PubMed Kispert JF, Kazmers A, Roitman L: Preoperative spirometry predicts perioperative pulmonary complications after major vascular surgery. Am Surg. 1992, 58: 491-495.PubMed
30.
go back to reference Sobin LH, Wittekind C: Pancreas. UICC/TNM classification of malignant tumors. Edited by: Sobin LH, Wittekind C. 1997, Heidelberg Springer Medizin, 87-90. Sobin LH, Wittekind C: Pancreas. UICC/TNM classification of malignant tumors. Edited by: Sobin LH, Wittekind C. 1997, Heidelberg Springer Medizin, 87-90.
31.
go back to reference Wittekind C, Meyer HJ, Bootz F: Pankreas. TNM Klassifikation maligner Tumoren. 2006, 83-85. Wittekind C, Meyer HJ, Bootz F: Pankreas. TNM Klassifikation maligner Tumoren. 2006, 83-85.
32.
go back to reference Buchler MW, Friess H, Wagner M, Kulli C, Wagener V, Z'Graggen K: Pancreatic fistula after pancreatic head resection. Br J Surg. 2000, 87: 883-889. 10.1046/j.1365-2168.2000.01465.x.CrossRefPubMed Buchler MW, Friess H, Wagner M, Kulli C, Wagener V, Z'Graggen K: Pancreatic fistula after pancreatic head resection. Br J Surg. 2000, 87: 883-889. 10.1046/j.1365-2168.2000.01465.x.CrossRefPubMed
33.
go back to reference Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, Buchler MW: Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995, 82: 1270-1273. 10.1002/bjs.1800820938.CrossRefPubMed Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, Buchler MW: Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995, 82: 1270-1273. 10.1002/bjs.1800820938.CrossRefPubMed
34.
go back to reference Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed
35.
go back to reference Ortiz-Gonzalez J, Alvarez-Aguila NP, Medina-Castro JM: Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. Anticancer Res. 2005, 25: 3625-3627.PubMed Ortiz-Gonzalez J, Alvarez-Aguila NP, Medina-Castro JM: Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. Anticancer Res. 2005, 25: 3625-3627.PubMed
36.
go back to reference Rai A, Tewari M, Mohapatra SC, Shukla HS: Correlation of nutritional parameters of gallbladder cancer patients. J Surg Oncol. 2006, 93: 705-708. 10.1002/jso.20539.CrossRefPubMed Rai A, Tewari M, Mohapatra SC, Shukla HS: Correlation of nutritional parameters of gallbladder cancer patients. J Surg Oncol. 2006, 93: 705-708. 10.1002/jso.20539.CrossRefPubMed
37.
go back to reference Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z'graggen K: Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003, 138: 1310-1314. 10.1001/archsurg.138.12.1310.CrossRefPubMed Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z'graggen K: Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003, 138: 1310-1314. 10.1001/archsurg.138.12.1310.CrossRefPubMed
Metadata
Title
Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function
Authors
Jeannine Bachmann
Knut Ketterer
Christiane Marsch
Kerstin Fechtner
Holger Krakowski-Roosen
Markus W Büchler
Helmut Friess
Marc E Martignoni
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-255

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine